Complimentary white paper to help marketers stay ahead of the digital marketing curve

Manhattan ResearchThe new year was ushered in amidst economic uncertainties and the impending inauguration of a new administration - the effects of which have great implications for the pharmaceutical industry. Brand managers especially will feel the heat as marketing spend and measurement is increasingly scrutinized. But despite the doom and gloom in predictions for the year ahead, physicians and patients will continue to use healthcare products and services and companies still need to find ways to effectively reach their target audiences.

Pharmaceutical and healthcare market research company Manhattan Research releases a complimentary white paper outlining the top New Year's resolutions for marketers looking to take advantage of the latest eHealth trends to better target physician and consumer groups and push their brand ahead on the digital marketing curve.

Top Five Pharma Brand Manager Resolutions:
1. Don't Forget About Search
2. Reassess Your Customer Service Model
3. Keep an Eye on Mobile
4. Think Outside of the Bag - A New Look at the Traditional Sales Force Model
5. Measure…and Keep Measuring!

Download the Full White Paper
"Pharma Brand Manager New Year’s Resolutions: Five Strategies for Staying Ahead in 2009" expands upon the above resolutions and reveals the latest eHealth tips and trends for improving brand strategies and connections with consumer and physician audiences. To access the full white paper, please visit: http://www.manhattanresearch.com/research/white-papers/
pharma-brand-manager-resolutions.aspx

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a global pharmaceutical and healthcare market research and strategic advisory firm. We conduct annual research studies covering eHealth trends among physicians and consumers, including Taking the Pulse®, Taking the Pulse® Europe, Taking the Pulse® Asia, ePharma Physician®, Cybercitizen Health™, Cybercitizen Health™ Europe, and ePharma Consumer®. Broad consumer and physician research is complemented by targeted analysis among more than 100 consumer therapeutic segments and 25 physician specialist segments.

For information, please visit www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

Most Popular Now

Johnson & Johnson announces advance purchase a…

Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vacci...

Pfizer and BioNTech confirm high efficacy and no s…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pi...

Pfizer-BioNTech announce positive topline results …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SAR...

GSK to support manufacture of Novavax' COVID-19 va…

GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax' COVID-19 va...

Valneva reports positive Phase 1/2 data for its in…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Clinical trial completion rates decline during COV…

Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected c...

BioNTech provides update on vaccine production sta…

BioNTech SE today announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. As part o...

Pfizer and BioNTech request regulatory agencies ex…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today requested amendments to the U.S. Emergency Use Authorization (EUA) of the Pfizer-BioNTech vaccine (BNT162b2) ...

COVID-19 convalescent plasma with greater antibody…

Convalescent plasma, the use of survivors' antibodies transfused into sick COVID-19 patients is safe and significantly improves clinical outcomes when using high levels o...

COVID-19 causes 'unexpected' cellular response in …

New insights into the immune response to SARS-CoV-2 infections could bring better treatments for COVID-19 cases. An international team of researchers unexpectedly foun...

Study identifies possible COVID-19 drugs - includi…

A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that ...

Undetected coronavirus variant was in at least 15 …

A highly contagious SARS-CoV-2 variant was unknowingly spreading for months in the United States by October 2020, according to a new study from researchers with The Unive...